NKGen Biotech

NKGen Biotech Net Margin

The Net Profit Margin of NKGen Biotech (NKGN) as of Nov 21, 2026 is -34,745.45 %. In the previous year, Net Profit Margin was -5,461.27 % — a change of 536.22% (lower).

Net Margin

-34,745.45 %

YoY

536.22%

Last updated:

Net Profit Margin of NKGen Biotech is 2022 -34,745.45 % . Net Profit Margin of NKGen Biotech was 2021 -5,461.27 % . It decreases by 536.22% lower compared to the previous year.

NKGen Biotech's net margin stands at -34,745.5%, down from -5,461.3% several years earlier.

The NKGen Biotech Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2021
-5,461.27 USD
Jan 1, 2022
-34,745.45 USD
The NKGen Biotech Net Margin history
YEARNet MarginYoY
-34,745.45 %+536.22%
-5,461.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Net Profit Margin of NKGen Biotech is -34,745.45 % in 2022.

Net Profit Margin of NKGen Biotech changed from -5,461.27 % to -34,745.45 %, representing a 536.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NKGen Biotech

All Key Metrics — NKGen Biotech